Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour? Shubham AtalZeenat FatimaSadasivam Balakrishnan Current Opinion 13 October 2020 Pages: 705 - 711
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease Ahmed AlmradiJurij HanzelVipul Jairath Leading Article 26 October 2020 Pages: 713 - 721
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? Daniel F. AlvarezGertjan WolbinkJonathan Kay Review Article Open access 29 September 2020 Pages: 723 - 732
The Immunotherapy Landscape in Renal Cell Carcinoma Landon C. BrownKunal DesaiMoshe C. Ornstein Review Article 13 October 2020 Pages: 733 - 748
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet? Tarek TahaAri ReissRuth Perets Review Article 03 November 2020 Pages: 749 - 762
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration Paula I. Fuller-CarterHamed BasiriLivia S. Carvalho Review Article 02 November 2020 Pages: 763 - 781
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption Liese BarbierSteven SimoensIsabelle Huys Original Research Article Open access 03 November 2020 Pages: 783 - 796
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice Liese BarbierSteven SimoensIsabelle Huys Original Research Article Open access 15 October 2020 Pages: 797 - 808
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study Piotr WilandSławomir JekaNorman B. Gaylis Original Research Article Open access 29 October 2020 Pages: 809 - 823
